GlassScriptPhysician profile
Peerawut Deeprasertkul
NPI 1144466111
$2,164.95
in general payments reported to CMS, 2019-2025
15 companies · $550 in 2025
The $550 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $96.14 · 2021: $46.72 · 2022: $354 · 2023: $716 · 2024: $403 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,668.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $855.22 | 2022-2024 | Gallant, Aveir, Ensite Precision |
| Biotronik INC. | $234.33 | 2025 | Biomonitor |
| Actelion Pharmaceuticals US, INC. | $196.14 | 2020-2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $168.01 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $152.74 | 2022-2025 | Capvaxive, Verquvo |
| Impulse Dynamics (USA) INC. | $124.36 | 2024 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $111.67 | 2021-2025 | Breztri |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $106.80 | 2023-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $46.70 | 2023-2025 | Camzyos, Eliquis, Empliciti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.16 | 2022 | |
| Pfizer INC. | $32.18 | 2023-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $30.73 | 2024 | Arcalyst |
| Amgen INC. | $29.92 | 2025 | Repatha |
| Irhythm Technologies, INC. | $18.58 | 2023 | Zio Xt Patch |
| Philips North America LLC | $14.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peerawut Deeprasertkul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.